ANIP241220P90000
- 0.00
- 0.000.00%
ANI Pharmaceuticals Newsroom
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect?
ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?
ANI Pharmaceuticals Advances Amidst Regulatory and Market Challenges
Have ANI Pharmaceuticals Insiders Been Selling Stock?
Ani Pharmaceuticals Insider Sold Shares Worth $375,050, According to a Recent SEC Filing
US Manufacturing Index Rises To 43, Highest Since 2020
ANI Pharmaceuticals Price Target Maintained With a $94.00/Share by HC Wainwright & Co.
ANI Pharmaceuticals Analyst Ratings
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $62
Truist Financial Remains a Hold on ANI Pharmaceuticals (ANIP)
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $94
ANI Pharmaceuticals: Buy Rating Backed by Consistent Revenue Growth, Strategic Acquisitions, and Strong Market Position
Express News | ANI Pharmaceuticals Inc : Piper Sandler Raises Target Price to $69 From $68
ANI Pharmaceuticals (NASDAQ:ANIP) Rallies 5.6% This Week, Taking Three-year Gains to 35%
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript Summary
ANI Pharmaceuticals' Record Growth and Strategic Acquisition
ANI Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals Q3 24 Earnings Conference Call At 8:00 AM ET